Dutch-English LEMS Tumor Association Prediction (DELTA-P) Score

The DELTA‑P score predicts the likelihood of underlying small‑cell lung cancer in patients newly diagnosed with Lambert‑Eaton myasthenic syndrome.

Dysarthria, dysphagia, chewing, neck weakness: bulbar weakness
Absent0Present+1
Erectile dysfunction
Female0Male - absent0Male - present+1
Loss of weight
Absent or < 5%0≥ 5%+1
Tobacco use at onset
Absent0Present+1
Age of onset, years
< 500≥ 50+1
Karnofsky performance score
70-10000-60+1

Indicações de Uso

Identifies in newly diagnosed LEMS patients their probability of underlying SCLC and guides intensity of early tumor screening. Applies at or within 3 months of symptom onset using six clinical predictors; high scores (4–6) indicate >93% SCLC risk, while 0–1 predicts ≤2.6% risk (derivation n=107; validation n=112; AUC ~94% 1 [Level I evidence]). Clinically useful for stratifying surveillance with CT‑thorax and FDG‑PET.

Insights e Precauções

Identifies high or low SCLC probability in newly diagnosed LEMS using six bedside variables. High discrimination (AUC ≈94% in derivation/validation cohorts) 1 [Level II evidence].
Cautions: Derived from two European cohorts only; performance drops in some real‑world settings; not a substitute for repeated thoracic imaging; SOX1 antibodies may add specificity; risk estimates become unreliable beyond early disease.